| ID | 1074 |
| Name of the vaccine | Pediarix |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 6 weeks to 6 years |
| Description of the vaccine | Diphtheria and Tetanus Toxoids and Acellular Pertussis adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
| Name of the manufacturing country | Belgium and Germany |
| Year of manufacture | 2002 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | Based on the immunogenicity of the individual antigens compared with licensed vaccines. |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses (0.5-mL each) at 2, 4, and 6 months of age. |
| Mechanism of action | Serum tetanus antitoxin level of greater than or equal to 0.1 IU/mL is protective.
|
| Route of administration | Intramuscular |
| Indications | Active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. |
| Export | Distributed by - GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | Aluminium salts |
| Repurposing | Could be used for diphtheria and pertussis. |
| Side effects of vaccine | Pain, redness, and swelling, fever, drowsiness, irritability and loss of appetite. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/79830/download |
| Other name | NA |
| Additional Links | https://www.drugs.com/pediarix.html
|